摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-[3-(1,3-Dioxolan-2-yl)phenoxy]propanamine | 73278-88-3

中文名称
——
中文别名
——
英文名称
3-[3-(1,3-Dioxolan-2-yl)phenoxy]propanamine
英文别名
3-<3-(1,3-dioxolan-1-yl)phenoxy>propylamine;3-[3-(1,3-dioxolan-2-yl)phenoxy]propylamine;3-[3-(1,3-dioxolan-2-yl)phenoxy]propan-1-amine
3-[3-(1,3-Dioxolan-2-yl)phenoxy]propanamine化学式
CAS
73278-88-3
化学式
C12H17NO3
mdl
——
分子量
223.272
InChiKey
DSJSKLRBUNEIAX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.7
  • 重原子数:
    16
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    53.7
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-[3-(1,3-Dioxolan-2-yl)phenoxy]propanamine盐酸 、 sodium tetrahydroborate 、 三乙胺 作用下, 以 甲醇正丁醇 为溶剂, 反应 3.0h, 生成 2-[3-[3-[(3-methylpiperidin-1-yl)methyl]phenoxy]propylamino]-1H-quinazolin-4-one
    参考文献:
    名称:
    4-喹唑啉酮衍生物的合成和组胺H2-拮抗剂活性。
    摘要:
    为了开发新的抗溃疡药物,合成了一系列4-喹唑啉酮衍生物,并测试了其组胺H2拮抗剂活性和胃抗分泌活性。因此,合成了2-烷基氨基(8a-d,10a-s)、2-烷基硫基(15)以及2-烷基-4-喹唑啉酮(18a-k),其方法分别是将烷基胺与2-氯或2-甲硫基-4-喹唑啉酮缩合、将烷基溴化物与2-巯基-4-喹唑啉酮缩合,以及将烷基羧酸与氨基苯甲酸酰胺缩合。合成的几种4-喹唑啉酮衍生物显示出强效的H2拮抗剂活性,其中一种2-[3-[3-(1-哌啶基甲基)苯氧]丙氨基]-4(3H)-喹唑啉酮(8d)表现出最强的抗分泌活性。讨论了结构-活性关系。
    DOI:
    10.1248/cpb.36.2955
  • 作为产物:
    参考文献:
    名称:
    MATSUMOTO, XADZIMEH;KASIVABA, NORIAKI;XOSODA, AKIXIKO;SEHKINEH, YASUO
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • 1,2,4-Triazole-3,5-diamine derivatives
    申请人:Glaxo Group Limited
    公开号:US04318913A1
    公开(公告)日:1982-03-09
    The invention relates to compounds of the formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in which R.sub.1 and R.sub.2 represent hydrogen, an aliphatic or cycloaliphatic group, or R.sub.1 and R.sub.2 together with the nitrogen atom form a 5 to 10 membered heterocyclic ring: Alk represents a straight or branched alkylene chain; Q represents furan, thiophen or benzene ring which is incorporated into the rest of the molecule; X represents --CH.sub.2 --, ##STR2## --O-- or --S-- where R.sub.6 represents hydrogen or methyl; n represents zero, 1 or 2; m represents 2, 3 or 4; R.sub.3 represents hydrogen, a substituted or unsubstituted aliphatic or aryl group and; R.sub.4 and R.sub.5, which may be the same or different, each represent hydrogen, a substituted or unsubstituted aliphatic, aryl, or together with the nitrogen atom form a heterocyclic group.
    该发明涉及式(I)的化合物及其生理上可接受的盐、水合物和生物前体,其中R.sub.1和R.sub.2代表氢、脂肪族或环脂族基团,或者R.sub.1和R.sub.2与氮原子一起形成5到10元杂环环:Alk代表直链或支链烷基链;Q代表噻吩或苯环,其嵌入到分子的其余部分中;X代表--CH.sub.2 --,--O--或--S--,其中R.sub.6代表氢或甲基;n代表零、1或2;m代表2、3或4;R.sub.3代表氢、取代或未取代的脂肪族或芳基团;R.sub.4和R.sub.5,可以相同也可以不同,每个代表氢、取代或未取代的脂肪族、芳基,或者与氮原子一起形成杂环基团。
  • Chemical intermediates and process
    申请人:Bristol-Myers Company
    公开号:US04927968A1
    公开(公告)日:1990-05-22
    The present invention relates to novel intermediates of the formula ##STR1## wherein R.sup.1 is hydrogen or lower alkyl and R is ##STR2## --CH.sub.2 OH or --CH.sub.2 X in which X is a conventional leaving group and Y is lower alkyl and the use thereof in a process for the preparation of certain histamine H.sub.2 -antagonists.
    本发明涉及公式##STR1##的新型中间体,其中R.sup.1是氢或较低的烷基,R是##STR2## --CH.sub.2 OH或--CH.sub.2 X,其中X是传统的离去基团,Y是较低的烷基,以及其在制备某些组胺H.sub.2 -拮抗剂的过程中的使用。
  • Triazole amine compounds, their pharmaceutical compositions and method
    申请人:Glaxo Group Limited
    公开号:US04670448A1
    公开(公告)日:1987-06-02
    The invention provides compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in which the substituents are defined in the detailed description. The compounds show pharmaceutical activity as selective histamine H.sub.2 -antagonists.
    该发明提供了一般式(I)的化合物##STR1##及其生理上可接受的盐、水合物和生物前体,在其中取代基在详细描述中定义。这些化合物显示了作为选择性组织胺H.sub.2受体拮抗剂的药理活性。
  • Phenoxypropyl derivatives
    申请人:Fujirebio Kabushiki Kaisha
    公开号:US04988828A1
    公开(公告)日:1991-01-29
    A phenoxypropyl derivative represented by the following formula ##STR1## wherein A represents a formyl group, a protected formyl group, a hydroxymethyl group, a protected hydroxymethyl group, or a halomethyl group, and Z represents a halogen atom, an amino group, a phthalimide group or a group of the formula ##STR2## in which n is 0, 1 or 2.
    以下是该句子的中文翻译: 一种由以下式子表示的苯氧基丙基衍生物:##STR1##其中A代表甲酰基、保护甲酰基、羟甲基、保护羟甲基或卤甲基;Z代表卤素原子、氨基、邻苯二甲酰亚胺基或式子##STR2##中的一个,其中n为0、1或2。
  • 1H-1,2,4-Triazole-3,5-diamine derivatives and use as selective histamine
    申请人:Glaxo Group Limited
    公开号:US04442110A1
    公开(公告)日:1984-04-10
    The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in which R.sub.1 and R.sub.2, which may be the same or different, each represent hydrogen, C.sub.1-10 alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, trifluoroalkyl or alkyl substituted by hydroxy, alkoxy, amino, alkylamino, dialkylamino or cycloalkyl, or R.sub.1 and R.sub.2 may together with the nitrogen atom to which they are attached form a 5 to 10 membered alicyclic heterocyclic ring which may be saturated or may contain at least one double bond, may be unsubstituted or may be substituted by one or more C.sub.1-3 alkyl groups or a hydroxy group and/or may contain another heteroatom; Alk represents a straight or branched alkylene chain of 1 to 6 carbon atoms; Q represents a furan or thiophen ring in which incorporation into the rest of the molecule is through bonds at the 2- and 5-positions, the furan ring optionally bearing a further substituent R.sub.7 adjacent to the group R.sub.1 R.sub.2 N-Alk-, or Q represents a benzene ring in which incorporation into the rest of the molecule is through bonds at the 1- and 3- or 1- and 4- positions; R.sub.7 represents halogen or C.sub.1-4 alkyl which may be substituted by hydroxy or C.sub.1-4 alkoxy; X represents --CH.sub.2 --, ##STR2## --O-- or --S-- where R.sub.6 represents hydrogen or methyl; n represents zero, 1 or 2; m represents 2, 3 or 4; R.sub.3 represents hydrogen, alkyl, alkenyl, aralkyl, hydroxyalkyl having at least two carbon atoms, alkoxyalkyl or aryl; and R.sub.4 and R.sub.5, which may be the same or different, each represent hydrogen, alkyl, alkyl substituted by hydroxy or C.sub.1-3 alkoxy, alkenyl, aralkyl or heteroaralkyl or R.sub.4 and R.sub.5 may together with the nitrogen atom to which they are attached form a 5 to 7-membered saturated heterocyclic ring which may contain another heteroatom, or the group ##STR3## or R.sub.4 and R.sub.5 taken together may represent the group .dbd.CR.sub.8 R.sub.9 where R.sub.8 represents aryl or heteroaryl and R.sub.9 represents hydrogen or alkyl. Preferably when X represents an oxygen atom or ##STR4## and n is zero, then Q only represents a benzene ring. The compounds of formula (I) show pharmacological activity as selective histamine H.sub.2 -antagonists.
    本发明涉及通式(I)的化合物,以及其生理上可接受的盐、水合物和生物前体,其中R.sub.1和R.sub.2,可以相同也可以不同,分别代表氢、C.sub.1-10烷基、环烷基、烯基、炔基、芳基烷基、三氟甲基或被羟基、烷氧基、氨基、烷基氨基、二烷基氨基或环烷基取代的烷基,或R.sub.1和R.sub.2可以与它们附着的氮原子一起形成一个5到10个成员的脂环杂环,该脂环杂环可以饱和或可以含有至少一个双键,可以是未取代的或可以被一个或多个C.sub.1-3烷基基团或羟基基团取代,也可以包含另一个杂原子;Alk代表1到6个碳原子的直链或支链烷基链;Q代表呋喃或噻吩环,其中结合到分子的其余部分是通过2-和5-位置的键,呋喃环可以选择地带有R.sub.1 R.sub.2 N-Alk-基团相邻的另一个取代基R.sub.7,或Q代表苯环,其中结合到分子的其余部分是通过1-和3-或1-和4-位置的键;R.sub.7代表卤素或C.sub.1-4烷基,可以被羟基或C.sub.1-4烷氧基取代;X代表--CH.sub.2 --、##STR2## --O--或--S--,其中R.sub.6代表氢或甲基;n代表零、1或2;m代表2、3或4;R.sub.3代表氢、烷基、烯基、芳基烷基、至少有两个碳原子的羟基烷基、烷氧基烷基或芳基;R.sub.4和R.sub.5,可以相同也可以不同,分别代表氢、烷基、被羟基或C.sub.1-3烷氧基取代的烷基、烯基、芳基烷基或杂芳基烷基,或R.sub.4和R.sub.5可以与它们附着的氮原子一起形成一个5到7个成员的饱和杂环,该杂环可以包含另一个杂原子,或者是基团##STR3##或R.sub.4和R.sub.5一起代表.dbd.CR.sub.8 R.sub.9基团,其中R.sub.8代表芳基或杂芳基,R.sub.9代表氢或烷基。当X代表氧原子或##STR4##且n为零时,最好Q仅代表苯环。公式(I)的化合物表现出选择性组胺H.sub.2-拮抗剂的药理活性。
查看更多